A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy

被引：0
|
作者：
White, JD
Cassidy, J
Twelves, C
Benson, C
Pacey, S
Judson, I
McGrath, H
Rose, F
Frenz, L
机构：
[1] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[2] Royal Marsden Hosp, RMH, Sutton, Surrey, England
[3] Canc Res UK, London, England
[4] Cyclacel Ltd, Dundee, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3042
引用
收藏
页码：205S / 205S
页数：1
相关论文
共 50 条
  • [41] Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
    Rastislav Bahleda
    Juneko E Grilley-Olson
    Ramaswamy Govindan
    Fabrice Barlesi
    Laurent Greillier
    Maurice Perol
    Isabelle Ray-Coquard
    Dirk Strumberg
    Beate Schultheis
    Grace K Dy
    Gérard Zalcman
    Glen J Weiss
    Annette O Walter
    Martin Kornacker
    Prabhu Rajagopalan
    David Henderson
    Hendrik Nogai
    Matthias Ocker
    Jean-Charles Soria
    British Journal of Cancer, 2017, 116 : 1505 - 1512
  • [42] Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
    Bahleda, Rastislav
    Grilley-Olson, Juneko E.
    Govindan, Ramaswamy
    Barlesi, Fabrice
    Greillier, Laurent
    Perol, Maurice
    Ray-Coquard, Isabelle
    Strumberg, Dirk
    Schultheis, Beate
    Dy, Grace K.
    Zalcman, Gerard
    Weiss, Glen J.
    Walter, Annette O.
    Kornacker, Martin
    Rajagopalan, Prabhu
    Henderson, David
    Nogai, Hendrik
    Ocker, Matthias
    Soria, Jean-Charles
    BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1505 - 1512
  • [43] A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC).
    Zhang, Pin
    Xu, Binghe
    Gui, Lin
    Wang, Wenna
    Xiu, Meng
    Zhang, Xiao
    Sun, Guilan
    Zhu, Xiaoyu
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] A phase I study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms: final report
    Hirte, H.
    Digumarti, R.
    Baetz, T.
    Hotte, S.
    Rajappa, S.
    Lacobucci, A.
    Moretto, P.
    Sharma, S.
    Parikh, H.
    Kulkarni, S.
    Patil, S.
    Padigaru, M.
    Kothekar, M.
    Porter, W.
    CANCER RESEARCH, 2009, 69
  • [45] Inhibition of cyclin dependent kinase-2 (CDK2) by CYC202 (R-Roscovitine) decreases cell proliferation but does not aggravate podocyte injury in experimental membranous nephropathy.
    Milovanceva-Popovska, M
    Kunter, U
    Ostendorf, T
    Petermann, A
    Rong, S
    Barnett, A
    Floege, J
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 342A - 342A
  • [46] Pharmacodynamic effects of seliciclib (r-roscovitine, cyc202) in patients with undifferentiated nasopharyngeal cancer (NPC) using a window trial design
    Hsieh, W. S.
    Peh, B. K.
    Loh, T.
    Chiao, J. H.
    Soo, R.
    Green, S. R.
    Lai, Y. F.
    Salto-Tellez, M.
    Soong, R.
    Goh, B. C.
    EJC SUPPLEMENTS, 2006, 4 (12): : 88 - 88
  • [47] Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
    Berkofsky-Fessler, Windy
    Nguyen, Tri Q.
    Delmar, Paul
    Molnos, Juliette
    Kanwal, Charu
    DePinto, Wanda
    Rosinski, James
    McLoughlin, Patricia
    Ritland, Steve
    DeMario, Mark
    Tobon, Krishna
    Reidhaar-Olson, John F.
    Rueger, Ruediger
    Hilton, Holly
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (09) : 2517 - 2525
  • [48] Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
    Mita, Monica M.
    Joy, Anil A.
    Mita, Alain
    Sankhala, Kamalesh
    Jou, Ying-Ming
    Zhang, Da
    Statkevich, Paul
    Zhu, Yali
    Yao, Siu-Long
    Small, Karen
    Bannerji, Rajat
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 169 - 176
  • [49] A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
    Chen, E. X.
    Hotte, S.
    Hirte, H.
    Siu, L. L.
    Lyons, J.
    Squires, M.
    Lovell, S.
    Turner, S.
    McIntosh, L.
    Seymour, L.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2262 - 2267
  • [50] A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
    Infante, Jeffrey R.
    Cassier, Philippe A.
    Gerecitano, John F.
    Witteveen, Petronella O.
    Chugh, Rashmi
    Ribrag, Vincent
    Chakraborty, Abhijit
    Matano, Alessandro
    Dobson, Jason R.
    Crystal, Adam S.
    Parasuraman, Sudha
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5696 - 5705
12345